Safety and efficacy of hydroxychloroquine for treatment of non-severe COVID-19 among adults in Uganda: a randomized open label phase II clinical trial

MLA

Pauline Byakika-Kibwika, et al. “Safety and Efficacy of Hydroxychloroquine for Treatment of Non-Severe COVID-19 among Adults in Uganda: A Randomized Open Label Phase II Clinical Trial.” BMC Infectious Diseases, vol. 21, no. 1, Dec. 2021, pp. 1–11. EBSCOhost, https://doi.org/10.1186/s12879-021-06897-9.

APA

Pauline Byakika-Kibwika, Christine Sekaggya-Wiltshire, Jerome Roy Semakula, Jane Nakibuuka, Joseph Musaazi, James Kayima, Cornelius Sendagire, David Meya, Bruce Kirenga, Sarah Nanzigu, Arthur Kwizera, Fred Nakwagala, Ivan Kisuule, Misaki Wayengera, Henry G. Mwebesa, Moses R. Kamya, & William Bazeyo. (2021). Safety and efficacy of hydroxychloroquine for treatment of non-severe COVID-19 among adults in Uganda: a randomized open label phase II clinical trial. BMC Infectious Diseases, 21(1), 1–11. https://doi.org/10.1186/s12879-021-06897-9

Chicago

Pauline Byakika-Kibwika, Christine Sekaggya-Wiltshire, Jerome Roy Semakula, Jane Nakibuuka, Joseph Musaazi, James Kayima, Cornelius Sendagire, et al. 2021. “Safety and Efficacy of Hydroxychloroquine for Treatment of Non-Severe COVID-19 among Adults in Uganda: A Randomized Open Label Phase II Clinical Trial.” BMC Infectious Diseases 21 (1): 1–11. doi:10.1186/s12879-021-06897-9.